nodes	percent_of_prediction	percent_of_DWPC	metapath
Gonadorelin—Goserelin—breast cancer	0.387	1	CrCtD
Gonadorelin—GNRHR—Goserelin—breast cancer	0.264	1	CbGbCtD
Gonadorelin—Icatibant—Goserelin—breast cancer	0.0887	0.314	CrCrCtD
Gonadorelin—Degarelix—Goserelin—breast cancer	0.0426	0.151	CrCrCtD
Gonadorelin—Pentagastrin—Goserelin—breast cancer	0.0426	0.151	CrCrCtD
Gonadorelin—Cetrorelix—Goserelin—breast cancer	0.0426	0.151	CrCrCtD
Gonadorelin—Ceruletide—Goserelin—breast cancer	0.0368	0.13	CrCrCtD
Gonadorelin—Nafarelin—Goserelin—breast cancer	0.0293	0.104	CrCrCtD
Gonadorelin—Pentagastrin—BCHE—breast cancer	0.000273	0.61	CrCbGaD
Gonadorelin—Desmopressin—PTGS1—breast cancer	0.000111	0.248	CrCbGaD
Gonadorelin—GNRHR—GPCR ligand binding—CXCL3—breast cancer	9.97e-05	0.00921	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CCL27—breast cancer	9.97e-05	0.00921	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL20—breast cancer	9.46e-05	0.00874	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRB—breast cancer	9.38e-05	0.00867	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—LPAR1—breast cancer	9.17e-05	0.00847	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR2—breast cancer	8.44e-05	0.00779	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—AGTR1—breast cancer	8.42e-05	0.00778	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—ITPR1—breast cancer	7.56e-05	0.00698	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—breast cancer	7.53e-05	0.00696	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL2—breast cancer	7.25e-05	0.0067	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR2—breast cancer	7.25e-05	0.0067	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CCL20—breast cancer	7.21e-05	0.00666	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—GPER1—breast cancer	7.09e-05	0.00655	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—LPAR1—breast cancer	6.98e-05	0.00645	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDNRB—breast cancer	6.95e-05	0.00642	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—STARD8—breast cancer	6.94e-05	0.00641	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—NMBR—breast cancer	6.8e-05	0.00628	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR1—breast cancer	6.76e-05	0.00624	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—breast cancer	6.71e-05	0.0062	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—GPER1—breast cancer	6.44e-05	0.00595	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CNR2—breast cancer	6.42e-05	0.00593	CbGpPWpGaD
Gonadorelin—Desmopressin—PTGS2—breast cancer	6.36e-05	0.142	CrCbGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PTGER1—breast cancer	6.32e-05	0.00584	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—NMBR—breast cancer	6.17e-05	0.0057	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR4—breast cancer	6.17e-05	0.0057	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL12—breast cancer	6.17e-05	0.0057	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—WNT1—breast cancer	6.04e-05	0.00558	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Melphalan—breast cancer	5.74e-05	0.00104	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PTGER1—breast cancer	5.74e-05	0.0053	CbGpPWpGaD
Gonadorelin—Fatigue—Melphalan—breast cancer	5.73e-05	0.00103	CcSEcCtD
Gonadorelin—Erythema—Gemcitabine—breast cancer	5.72e-05	0.00103	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Vinblastine—breast cancer	5.72e-05	0.00103	CcSEcCtD
Gonadorelin—Nervous system disorder—Vinorelbine—breast cancer	5.7e-05	0.00103	CcSEcCtD
Gonadorelin—Pain—Melphalan—breast cancer	5.69e-05	0.00103	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—CCL27—breast cancer	5.63e-05	0.0052	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—CXCL3—breast cancer	5.63e-05	0.0052	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PDE2A—breast cancer	5.63e-05	0.0052	CbGpPWpGaD
Gonadorelin—Erythema—Fluorouracil—breast cancer	5.62e-05	0.00101	CcSEcCtD
Gonadorelin—Hypersensitivity—Chlorambucil—breast cancer	5.62e-05	0.00101	CcSEcCtD
Gonadorelin—Nausea—Raloxifene—breast cancer	5.59e-05	0.00101	CcSEcCtD
Gonadorelin—Nausea—Idarubicin—breast cancer	5.59e-05	0.00101	CcSEcCtD
Gonadorelin—Fatigue—Goserelin—breast cancer	5.59e-05	0.00101	CcSEcCtD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR1—breast cancer	5.58e-05	0.00515	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Tamoxifen—breast cancer	5.55e-05	0.001	CcSEcCtD
Gonadorelin—Constipation—Goserelin—breast cancer	5.55e-05	0.001	CcSEcCtD
Gonadorelin—Pain—Goserelin—breast cancer	5.55e-05	0.001	CcSEcCtD
Gonadorelin—Abdominal pain—Vinblastine—breast cancer	5.53e-05	0.000997	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—AGTR2—breast cancer	5.52e-05	0.0051	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CXCL2—breast cancer	5.52e-05	0.0051	CbGpPWpGaD
Gonadorelin—Asthenia—Chlorambucil—breast cancer	5.47e-05	0.000988	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—PTHLH—breast cancer	5.46e-05	0.00505	CbGpPWpGaD
Gonadorelin—Nervous system disorder—Thiotepa—breast cancer	5.44e-05	0.000982	CcSEcCtD
Gonadorelin—Abdominal discomfort—Capecitabine—breast cancer	5.41e-05	0.000976	CcSEcCtD
Gonadorelin—Pruritus—Chlorambucil—breast cancer	5.4e-05	0.000974	CcSEcCtD
Gonadorelin—Abdominal pain—Tamoxifen—breast cancer	5.37e-05	0.000969	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Goserelin—breast cancer	5.3e-05	0.000957	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—EDNRB—breast cancer	5.29e-05	0.00489	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—WNT10B—breast cancer	5.25e-05	0.00485	CbGpPWpGaD
Gonadorelin—Upper respiratory tract infection—Capecitabine—breast cancer	5.24e-05	0.000946	CcSEcCtD
Gonadorelin—Diarrhoea—Chlorambucil—breast cancer	5.22e-05	0.000942	CcSEcCtD
Gonadorelin—Hypersensitivity—Vinblastine—breast cancer	5.15e-05	0.00093	CcSEcCtD
Gonadorelin—Abdominal pain—Goserelin—breast cancer	5.13e-05	0.000925	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—CCL27—breast cancer	5.12e-05	0.00473	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CXCL3—breast cancer	5.12e-05	0.00473	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PDE2A—breast cancer	5.12e-05	0.00473	CbGpPWpGaD
Gonadorelin—Asthenia—Vinblastine—breast cancer	5.02e-05	0.000905	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Vinorelbine—breast cancer	5.02e-05	0.000905	CcSEcCtD
Gonadorelin—Fatigue—Vinorelbine—breast cancer	5.01e-05	0.000904	CcSEcCtD
Gonadorelin—Hypersensitivity—Tamoxifen—breast cancer	5e-05	0.000903	CcSEcCtD
Gonadorelin—Angiopathy—Paclitaxel—breast cancer	4.99e-05	0.000901	CcSEcCtD
Gonadorelin—Constipation—Vinorelbine—breast cancer	4.97e-05	0.000897	CcSEcCtD
Gonadorelin—Pain—Vinorelbine—breast cancer	4.97e-05	0.000897	CcSEcCtD
Gonadorelin—Immune system disorder—Paclitaxel—breast cancer	4.97e-05	0.000897	CcSEcCtD
Gonadorelin—Hypersensitivity—Melphalan—breast cancer	4.9e-05	0.000884	CcSEcCtD
Gonadorelin—Asthenia—Tamoxifen—breast cancer	4.87e-05	0.000879	CcSEcCtD
Gonadorelin—Vomiting—Chlorambucil—breast cancer	4.85e-05	0.000875	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—CALCA—breast cancer	4.81e-05	0.00444	CbGpPWpGaD
Gonadorelin—Pruritus—Tamoxifen—breast cancer	4.8e-05	0.000867	CcSEcCtD
Gonadorelin—Anaphylactic shock—Mitoxantrone—breast cancer	4.79e-05	0.000865	CcSEcCtD
Gonadorelin—Anaphylactic shock—Irinotecan—breast cancer	4.79e-05	0.000865	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Thiotepa—breast cancer	4.79e-05	0.000864	CcSEcCtD
Gonadorelin—Erythema—Paclitaxel—breast cancer	4.79e-05	0.000864	CcSEcCtD
Gonadorelin—Fatigue—Thiotepa—breast cancer	4.78e-05	0.000863	CcSEcCtD
Gonadorelin—Diarrhoea—Vinblastine—breast cancer	4.78e-05	0.000863	CcSEcCtD
Gonadorelin—Hypersensitivity—Goserelin—breast cancer	4.78e-05	0.000863	CcSEcCtD
Gonadorelin—Asthenia—Melphalan—breast cancer	4.77e-05	0.000861	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Vinorelbine—breast cancer	4.75e-05	0.000857	CcSEcCtD
Gonadorelin—Pain—Thiotepa—breast cancer	4.74e-05	0.000856	CcSEcCtD
Gonadorelin—Constipation—Thiotepa—breast cancer	4.74e-05	0.000856	CcSEcCtD
Gonadorelin—Flatulence—Paclitaxel—breast cancer	4.72e-05	0.000852	CcSEcCtD
Gonadorelin—Shock—Irinotecan—breast cancer	4.71e-05	0.000851	CcSEcCtD
Gonadorelin—Shock—Mitoxantrone—breast cancer	4.71e-05	0.000851	CcSEcCtD
Gonadorelin—Pruritus—Melphalan—breast cancer	4.7e-05	0.000849	CcSEcCtD
Gonadorelin—Nervous system disorder—Irinotecan—breast cancer	4.7e-05	0.000848	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—CXCR4—breast cancer	4.7e-05	0.00434	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CXCL12—breast cancer	4.7e-05	0.00434	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Gemcitabine—breast cancer	4.67e-05	0.000842	CcSEcCtD
Gonadorelin—Asthenia—Goserelin—breast cancer	4.65e-05	0.00084	CcSEcCtD
Gonadorelin—Diarrhoea—Tamoxifen—breast cancer	4.65e-05	0.000839	CcSEcCtD
Gonadorelin—Abdominal pain—Vinorelbine—breast cancer	4.59e-05	0.000829	CcSEcCtD
Gonadorelin—Pruritus—Goserelin—breast cancer	4.59e-05	0.000828	CcSEcCtD
Gonadorelin—Anaphylactic shock—Fluorouracil—breast cancer	4.59e-05	0.000828	CcSEcCtD
Gonadorelin—Nervous system disorder—Gemcitabine—breast cancer	4.58e-05	0.000826	CcSEcCtD
Gonadorelin—Diarrhoea—Melphalan—breast cancer	4.55e-05	0.000821	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Thiotepa—breast cancer	4.54e-05	0.000819	CcSEcCtD
Gonadorelin—Nausea—Chlorambucil—breast cancer	4.53e-05	0.000818	CcSEcCtD
Gonadorelin—Nervous system disorder—Fluorouracil—breast cancer	4.5e-05	0.000812	CcSEcCtD
Gonadorelin—Vomiting—Vinblastine—breast cancer	4.44e-05	0.000802	CcSEcCtD
Gonadorelin—Diarrhoea—Goserelin—breast cancer	4.44e-05	0.000801	CcSEcCtD
Gonadorelin—Breast disorder—Methotrexate—breast cancer	4.39e-05	0.000792	CcSEcCtD
Gonadorelin—Abdominal pain—Thiotepa—breast cancer	4.39e-05	0.000792	CcSEcCtD
Gonadorelin—Headache—Vinblastine—breast cancer	4.38e-05	0.00079	CcSEcCtD
Gonadorelin—Vomiting—Tamoxifen—breast cancer	4.32e-05	0.000779	CcSEcCtD
Gonadorelin—Hypersensitivity—Vinorelbine—breast cancer	4.28e-05	0.000773	CcSEcCtD
Gonadorelin—Headache—Tamoxifen—breast cancer	4.25e-05	0.000768	CcSEcCtD
Gonadorelin—GNRHR—GPCR ligand binding—AGTR1—breast cancer	4.25e-05	0.00392	CbGpPWpGaD
Gonadorelin—Angiopathy—Docetaxel—breast cancer	4.23e-05	0.000763	CcSEcCtD
Gonadorelin—Vomiting—Melphalan—breast cancer	4.23e-05	0.000763	CcSEcCtD
Gonadorelin—Immune system disorder—Docetaxel—breast cancer	4.21e-05	0.00076	CcSEcCtD
Gonadorelin—Asthenia—Vinorelbine—breast cancer	4.17e-05	0.000752	CcSEcCtD
Gonadorelin—Nausea—Vinblastine—breast cancer	4.15e-05	0.000749	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Irinotecan—breast cancer	4.14e-05	0.000747	CcSEcCtD
Gonadorelin—Fatigue—Irinotecan—breast cancer	4.13e-05	0.000746	CcSEcCtD
Gonadorelin—Fatigue—Mitoxantrone—breast cancer	4.13e-05	0.000746	CcSEcCtD
Gonadorelin—Vomiting—Goserelin—breast cancer	4.12e-05	0.000744	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—RGS2—breast cancer	4.12e-05	0.0038	CbGpPWpGaD
Gonadorelin—Pruritus—Vinorelbine—breast cancer	4.11e-05	0.000742	CcSEcCtD
Gonadorelin—Breast disorder—Epirubicin—breast cancer	4.11e-05	0.000741	CcSEcCtD
Gonadorelin—Pain—Irinotecan—breast cancer	4.1e-05	0.000739	CcSEcCtD
Gonadorelin—Constipation—Irinotecan—breast cancer	4.1e-05	0.000739	CcSEcCtD
Gonadorelin—Pain—Mitoxantrone—breast cancer	4.1e-05	0.000739	CcSEcCtD
Gonadorelin—Constipation—Mitoxantrone—breast cancer	4.1e-05	0.000739	CcSEcCtD
Gonadorelin—Angiopathy—Capecitabine—breast cancer	4.1e-05	0.000739	CcSEcCtD
Gonadorelin—Hypersensitivity—Thiotepa—breast cancer	4.09e-05	0.000738	CcSEcCtD
Gonadorelin—Immune system disorder—Capecitabine—breast cancer	4.08e-05	0.000736	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—CCL20—breast cancer	4.07e-05	0.00376	CbGpPWpGaD
Gonadorelin—Headache—Goserelin—breast cancer	4.06e-05	0.000733	CcSEcCtD
Gonadorelin—Erythema—Docetaxel—breast cancer	4.06e-05	0.000732	CcSEcCtD
Gonadorelin—Nausea—Tamoxifen—breast cancer	4.03e-05	0.000728	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Gemcitabine—breast cancer	4.03e-05	0.000727	CcSEcCtD
Gonadorelin—Abdominal discomfort—Methotrexate—breast cancer	4.02e-05	0.000726	CcSEcCtD
Gonadorelin—Fatigue—Gemcitabine—breast cancer	4.02e-05	0.000726	CcSEcCtD
Gonadorelin—Pain—Gemcitabine—breast cancer	3.99e-05	0.00072	CcSEcCtD
Gonadorelin—Constipation—Gemcitabine—breast cancer	3.99e-05	0.00072	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—LGR6—breast cancer	3.99e-05	0.00368	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CCDC88C—breast cancer	3.99e-05	0.00368	CbGpPWpGaD
Gonadorelin—Asthenia—Thiotepa—breast cancer	3.98e-05	0.000718	CcSEcCtD
Gonadorelin—Diarrhoea—Vinorelbine—breast cancer	3.98e-05	0.000717	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Fluorouracil—breast cancer	3.96e-05	0.000715	CcSEcCtD
Gonadorelin—Nausea—Melphalan—breast cancer	3.95e-05	0.000713	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—LPAR1—breast cancer	3.94e-05	0.00364	CbGpPWpGaD
Gonadorelin—Erythema—Capecitabine—breast cancer	3.93e-05	0.000709	CcSEcCtD
Gonadorelin—Pruritus—Thiotepa—breast cancer	3.93e-05	0.000708	CcSEcCtD
Gonadorelin—Pain—Fluorouracil—breast cancer	3.92e-05	0.000708	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Mitoxantrone—breast cancer	3.92e-05	0.000707	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Irinotecan—breast cancer	3.92e-05	0.000707	CcSEcCtD
Gonadorelin—Anaphylactic shock—Paclitaxel—breast cancer	3.91e-05	0.000705	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Methotrexate—breast cancer	3.9e-05	0.000704	CcSEcCtD
Gonadorelin—Flatulence—Capecitabine—breast cancer	3.87e-05	0.000699	CcSEcCtD
Gonadorelin—Nausea—Goserelin—breast cancer	3.85e-05	0.000695	CcSEcCtD
Gonadorelin—Shock—Paclitaxel—breast cancer	3.84e-05	0.000694	CcSEcCtD
Gonadorelin—Nervous system disorder—Paclitaxel—breast cancer	3.83e-05	0.000692	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—SFRP1—breast cancer	3.8e-05	0.00351	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GPER1—breast cancer	3.8e-05	0.00351	CbGpPWpGaD
Gonadorelin—Breast disorder—Doxorubicin—breast cancer	3.8e-05	0.000686	CcSEcCtD
Gonadorelin—Diarrhoea—Thiotepa—breast cancer	3.8e-05	0.000685	CcSEcCtD
Gonadorelin—Abdominal pain—Mitoxantrone—breast cancer	3.79e-05	0.000684	CcSEcCtD
Gonadorelin—Abdominal pain—Irinotecan—breast cancer	3.79e-05	0.000684	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—RGS2—breast cancer	3.74e-05	0.00346	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PDE4D—breast cancer	3.73e-05	0.00344	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CCL20—breast cancer	3.7e-05	0.00342	CbGpPWpGaD
Gonadorelin—Vomiting—Vinorelbine—breast cancer	3.69e-05	0.000667	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—breast cancer	3.68e-05	0.0034	CbGpPWpGaD
Gonadorelin—Upper respiratory tract infection—Epirubicin—breast cancer	3.65e-05	0.000659	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—NMBR—breast cancer	3.65e-05	0.00337	CbGpPWpGaD
Gonadorelin—Headache—Vinorelbine—breast cancer	3.64e-05	0.000657	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—CNR2—breast cancer	3.63e-05	0.00335	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—LPAR1—breast cancer	3.58e-05	0.00331	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Mitoxantrone—breast cancer	3.53e-05	0.000637	CcSEcCtD
Gonadorelin—Hypersensitivity—Irinotecan—breast cancer	3.53e-05	0.000637	CcSEcCtD
Gonadorelin—Vomiting—Thiotepa—breast cancer	3.53e-05	0.000637	CcSEcCtD
Gonadorelin—Headache—Thiotepa—breast cancer	3.48e-05	0.000627	CcSEcCtD
Gonadorelin—Nausea—Vinorelbine—breast cancer	3.45e-05	0.000623	CcSEcCtD
Gonadorelin—Asthenia—Mitoxantrone—breast cancer	3.44e-05	0.00062	CcSEcCtD
Gonadorelin—Asthenia—Irinotecan—breast cancer	3.44e-05	0.00062	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—HEYL—breast cancer	3.39e-05	0.00313	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PTGER1—breast cancer	3.39e-05	0.00313	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CUL5—breast cancer	3.39e-05	0.00313	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PDE4D—breast cancer	3.38e-05	0.00312	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Fluorouracil—breast cancer	3.38e-05	0.00061	CcSEcCtD
Gonadorelin—Upper respiratory tract infection—Doxorubicin—breast cancer	3.38e-05	0.00061	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Paclitaxel—breast cancer	3.37e-05	0.000609	CcSEcCtD
Gonadorelin—Fatigue—Paclitaxel—breast cancer	3.37e-05	0.000608	CcSEcCtD
Gonadorelin—Asthenia—Gemcitabine—breast cancer	3.35e-05	0.000604	CcSEcCtD
Gonadorelin—Pain—Paclitaxel—breast cancer	3.34e-05	0.000603	CcSEcCtD
Gonadorelin—Constipation—Paclitaxel—breast cancer	3.34e-05	0.000603	CcSEcCtD
Gonadorelin—Anaphylactic shock—Docetaxel—breast cancer	3.31e-05	0.000598	CcSEcCtD
Gonadorelin—Pruritus—Gemcitabine—breast cancer	3.3e-05	0.000596	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—CNR2—breast cancer	3.3e-05	0.00305	CbGpPWpGaD
Gonadorelin—Nausea—Thiotepa—breast cancer	3.3e-05	0.000595	CcSEcCtD
Gonadorelin—Diarrhoea—Irinotecan—breast cancer	3.28e-05	0.000592	CcSEcCtD
Gonadorelin—Diarrhoea—Mitoxantrone—breast cancer	3.28e-05	0.000592	CcSEcCtD
Gonadorelin—Shock—Docetaxel—breast cancer	3.26e-05	0.000588	CcSEcCtD
Gonadorelin—Nervous system disorder—Docetaxel—breast cancer	3.25e-05	0.000586	CcSEcCtD
Gonadorelin—Pruritus—Fluorouracil—breast cancer	3.25e-05	0.000586	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Paclitaxel—breast cancer	3.2e-05	0.000577	CcSEcCtD
Gonadorelin—Diarrhoea—Gemcitabine—breast cancer	3.19e-05	0.000576	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—RSPO3—breast cancer	3.19e-05	0.00294	CbGpPWpGaD
Gonadorelin—Shock—Capecitabine—breast cancer	3.16e-05	0.000569	CcSEcCtD
Gonadorelin—Nervous system disorder—Capecitabine—breast cancer	3.14e-05	0.000568	CcSEcCtD
Gonadorelin—Diarrhoea—Fluorouracil—breast cancer	3.14e-05	0.000567	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—CXCL2—breast cancer	3.12e-05	0.00288	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AGTR2—breast cancer	3.12e-05	0.00288	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—WWOX—breast cancer	3.1e-05	0.00286	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—WNT10B—breast cancer	3.1e-05	0.00286	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—WNT1—breast cancer	3.1e-05	0.00286	CbGpPWpGaD
Gonadorelin—Abdominal pain—Paclitaxel—breast cancer	3.09e-05	0.000558	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—PTHLH—breast cancer	3.09e-05	0.00285	CbGpPWpGaD
Gonadorelin—Angiopathy—Methotrexate—breast cancer	3.05e-05	0.00055	CcSEcCtD
Gonadorelin—Vomiting—Mitoxantrone—breast cancer	3.05e-05	0.00055	CcSEcCtD
Gonadorelin—Vomiting—Irinotecan—breast cancer	3.05e-05	0.00055	CcSEcCtD
Gonadorelin—Immune system disorder—Methotrexate—breast cancer	3.04e-05	0.000548	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PDE2A—breast cancer	3.02e-05	0.00279	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CXCL3—breast cancer	3.02e-05	0.00279	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—INHBB—breast cancer	3.02e-05	0.00279	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CCL27—breast cancer	3.02e-05	0.00279	CbGpPWpGaD
Gonadorelin—Headache—Irinotecan—breast cancer	3e-05	0.000542	CcSEcCtD
Gonadorelin—Headache—Mitoxantrone—breast cancer	3e-05	0.000542	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—EDNRB—breast cancer	2.99e-05	0.00276	CbGpPWpGaD
Gonadorelin—Vomiting—Gemcitabine—breast cancer	2.97e-05	0.000536	CcSEcCtD
Gonadorelin—Erythema—Methotrexate—breast cancer	2.93e-05	0.000528	CcSEcCtD
Gonadorelin—Headache—Gemcitabine—breast cancer	2.92e-05	0.000528	CcSEcCtD
Gonadorelin—Vomiting—Fluorouracil—breast cancer	2.92e-05	0.000527	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—DLL4—breast cancer	2.88e-05	0.00266	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—BMPR2—breast cancer	2.88e-05	0.00266	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Paclitaxel—breast cancer	2.88e-05	0.00052	CcSEcCtD
Gonadorelin—Headache—Fluorouracil—breast cancer	2.87e-05	0.000519	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Docetaxel—breast cancer	2.86e-05	0.000516	CcSEcCtD
Gonadorelin—Fatigue—Docetaxel—breast cancer	2.86e-05	0.000515	CcSEcCtD
Gonadorelin—Angiopathy—Epirubicin—breast cancer	2.85e-05	0.000515	CcSEcCtD
Gonadorelin—Nausea—Irinotecan—breast cancer	2.85e-05	0.000514	CcSEcCtD
Gonadorelin—Nausea—Mitoxantrone—breast cancer	2.85e-05	0.000514	CcSEcCtD
Gonadorelin—Immune system disorder—Epirubicin—breast cancer	2.84e-05	0.000513	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—CXCL2—breast cancer	2.83e-05	0.00262	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AGTR2—breast cancer	2.83e-05	0.00262	CbGpPWpGaD
Gonadorelin—Pain—Docetaxel—breast cancer	2.83e-05	0.000511	CcSEcCtD
Gonadorelin—Constipation—Docetaxel—breast cancer	2.83e-05	0.000511	CcSEcCtD
Gonadorelin—Asthenia—Paclitaxel—breast cancer	2.8e-05	0.000506	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PTHLH—breast cancer	2.8e-05	0.00259	CbGpPWpGaD
Gonadorelin—Nausea—Gemcitabine—breast cancer	2.77e-05	0.0005	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Capecitabine—breast cancer	2.77e-05	0.0005	CcSEcCtD
Gonadorelin—Fatigue—Capecitabine—breast cancer	2.76e-05	0.000499	CcSEcCtD
Gonadorelin—Pruritus—Paclitaxel—breast cancer	2.76e-05	0.000499	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—CDH5—breast cancer	2.76e-05	0.00255	CbGpPWpGaD
Gonadorelin—Pain—Capecitabine—breast cancer	2.74e-05	0.000495	CcSEcCtD
Gonadorelin—Constipation—Capecitabine—breast cancer	2.74e-05	0.000495	CcSEcCtD
Gonadorelin—Erythema—Epirubicin—breast cancer	2.74e-05	0.000494	CcSEcCtD
Gonadorelin—Nausea—Fluorouracil—breast cancer	2.73e-05	0.000492	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—CALCA—breast cancer	2.72e-05	0.00251	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—EDNRB—breast cancer	2.71e-05	0.00251	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SFRP2—breast cancer	2.71e-05	0.0025	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Docetaxel—breast cancer	2.71e-05	0.000489	CcSEcCtD
Gonadorelin—Flatulence—Epirubicin—breast cancer	2.7e-05	0.000487	CcSEcCtD
Gonadorelin—Diarrhoea—Paclitaxel—breast cancer	2.67e-05	0.000483	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PRLR—breast cancer	2.66e-05	0.00246	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—CXCL12—breast cancer	2.65e-05	0.00245	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—CXCR4—breast cancer	2.65e-05	0.00245	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—breast cancer	2.65e-05	0.00245	CbGpPWpGaD
Gonadorelin—Angiopathy—Doxorubicin—breast cancer	2.64e-05	0.000476	CcSEcCtD
Gonadorelin—Immune system disorder—Doxorubicin—breast cancer	2.63e-05	0.000474	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Capecitabine—breast cancer	2.62e-05	0.000473	CcSEcCtD
Gonadorelin—Abdominal pain—Docetaxel—breast cancer	2.62e-05	0.000473	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—GLI2—breast cancer	2.57e-05	0.00237	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—VCP—breast cancer	2.57e-05	0.00237	CbGpPWpGaD
Gonadorelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—breast cancer	2.56e-05	0.00236	CbGpPWpGaD
Gonadorelin—Abdominal pain—Capecitabine—breast cancer	2.54e-05	0.000458	CcSEcCtD
Gonadorelin—Erythema—Doxorubicin—breast cancer	2.53e-05	0.000457	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—LEPR—breast cancer	2.53e-05	0.00234	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—breast cancer	2.52e-05	0.00233	CbGpPWpGaD
Gonadorelin—Flatulence—Doxorubicin—breast cancer	2.5e-05	0.00045	CcSEcCtD
Gonadorelin—Vomiting—Paclitaxel—breast cancer	2.48e-05	0.000448	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—CALCA—breast cancer	2.47e-05	0.00228	CbGpPWpGaD
Gonadorelin—GNRHR—G alpha (q) signalling events—PIK3CA—breast cancer	2.45e-05	0.00226	CbGpPWpGaD
Gonadorelin—Headache—Paclitaxel—breast cancer	2.45e-05	0.000442	CcSEcCtD
Gonadorelin—Hypersensitivity—Docetaxel—breast cancer	2.44e-05	0.00044	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—CXCL12—breast cancer	2.41e-05	0.00223	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CXCR4—breast cancer	2.41e-05	0.00223	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AGTR1—breast cancer	2.4e-05	0.00222	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Methotrexate—breast cancer	2.39e-05	0.000431	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—breast cancer	2.38e-05	0.0022	CbGpPWpGaD
Gonadorelin—Asthenia—Docetaxel—breast cancer	2.38e-05	0.000429	CcSEcCtD
Gonadorelin—Hypersensitivity—Capecitabine—breast cancer	2.36e-05	0.000426	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—ARHGDIA—breast cancer	2.35e-05	0.00217	CbGpPWpGaD
Gonadorelin—Pruritus—Docetaxel—breast cancer	2.34e-05	0.000423	CcSEcCtD
Gonadorelin—Nervous system disorder—Methotrexate—breast cancer	2.34e-05	0.000423	CcSEcCtD
Gonadorelin—Nausea—Paclitaxel—breast cancer	2.32e-05	0.000419	CcSEcCtD
Gonadorelin—Asthenia—Capecitabine—breast cancer	2.3e-05	0.000415	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—FST—breast cancer	2.29e-05	0.00212	CbGpPWpGaD
Gonadorelin—Pruritus—Capecitabine—breast cancer	2.27e-05	0.000409	CcSEcCtD
Gonadorelin—Diarrhoea—Docetaxel—breast cancer	2.27e-05	0.000409	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—HEY2—breast cancer	2.26e-05	0.00209	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RPS6KB2—breast cancer	2.24e-05	0.00206	CbGpPWpGaD
Gonadorelin—Anaphylactic shock—Epirubicin—breast cancer	2.23e-05	0.000403	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—RGS2—breast cancer	2.21e-05	0.00204	CbGpPWpGaD
Gonadorelin—Shock—Epirubicin—breast cancer	2.2e-05	0.000397	CcSEcCtD
Gonadorelin—Diarrhoea—Capecitabine—breast cancer	2.19e-05	0.000396	CcSEcCtD
Gonadorelin—Nervous system disorder—Epirubicin—breast cancer	2.19e-05	0.000395	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—breast cancer	2.19e-05	0.00202	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CCL20—breast cancer	2.18e-05	0.00202	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AGTR1—breast cancer	2.18e-05	0.00201	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—ITPR1—breast cancer	2.15e-05	0.00199	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TLE3—breast cancer	2.12e-05	0.00195	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—LPAR1—breast cancer	2.12e-05	0.00195	CbGpPWpGaD
Gonadorelin—Vomiting—Docetaxel—breast cancer	2.11e-05	0.00038	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—HEY1—breast cancer	2.09e-05	0.00193	CbGpPWpGaD
Gonadorelin—Headache—Docetaxel—breast cancer	2.07e-05	0.000374	CcSEcCtD
Gonadorelin—Anaphylactic shock—Doxorubicin—breast cancer	2.07e-05	0.000373	CcSEcCtD
Gonadorelin—Gastrointestinal disorder—Methotrexate—breast cancer	2.06e-05	0.000372	CcSEcCtD
Gonadorelin—Fatigue—Methotrexate—breast cancer	2.06e-05	0.000371	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—DLL1—breast cancer	2.05e-05	0.0019	CbGpPWpGaD
Gonadorelin—Pain—Methotrexate—breast cancer	2.04e-05	0.000368	CcSEcCtD
Gonadorelin—Vomiting—Capecitabine—breast cancer	2.04e-05	0.000368	CcSEcCtD
Gonadorelin—Shock—Doxorubicin—breast cancer	2.03e-05	0.000367	CcSEcCtD
Gonadorelin—Nervous system disorder—Doxorubicin—breast cancer	2.03e-05	0.000366	CcSEcCtD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—breast cancer	2.03e-05	0.00187	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HIST1H2BC—breast cancer	2.02e-05	0.00186	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HIST1H2BK—breast cancer	2.02e-05	0.00186	CbGpPWpGaD
Gonadorelin—Headache—Capecitabine—breast cancer	2.01e-05	0.000363	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—GRB7—breast cancer	2e-05	0.00185	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PDE4D—breast cancer	2e-05	0.00185	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—CSF2—breast cancer	1.99e-05	0.00184	CbGpPWpGaD
Gonadorelin—Nausea—Docetaxel—breast cancer	1.97e-05	0.000355	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—TAB2—breast cancer	1.96e-05	0.00181	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—ITPR1—breast cancer	1.96e-05	0.00181	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Methotrexate—breast cancer	1.95e-05	0.000352	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—CNR2—breast cancer	1.95e-05	0.0018	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR ligand binding—CXCL8—breast cancer	1.95e-05	0.0018	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—MMP3—breast cancer	1.94e-05	0.00179	CbGpPWpGaD
Gonadorelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—breast cancer	1.94e-05	0.00179	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Epirubicin—breast cancer	1.93e-05	0.000348	CcSEcCtD
Gonadorelin—Fatigue—Epirubicin—breast cancer	1.93e-05	0.000348	CcSEcCtD
Gonadorelin—Pain—Epirubicin—breast cancer	1.91e-05	0.000345	CcSEcCtD
Gonadorelin—Constipation—Epirubicin—breast cancer	1.91e-05	0.000345	CcSEcCtD
Gonadorelin—Nausea—Capecitabine—breast cancer	1.9e-05	0.000344	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—DKK1—breast cancer	1.9e-05	0.00176	CbGpPWpGaD
Gonadorelin—Abdominal pain—Methotrexate—breast cancer	1.89e-05	0.000341	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—VEGFC—breast cancer	1.89e-05	0.00174	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—JAG2—breast cancer	1.86e-05	0.00172	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—WNT1—breast cancer	1.83e-05	0.00169	CbGpPWpGaD
Gonadorelin—Gastrointestinal pain—Epirubicin—breast cancer	1.83e-05	0.00033	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PLA2G4A—breast cancer	1.83e-05	0.00169	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CSF2—breast cancer	1.81e-05	0.00167	CbGpPWpGaD
Gonadorelin—Gastrointestinal disorder—Doxorubicin—breast cancer	1.78e-05	0.000322	CcSEcCtD
Gonadorelin—Fatigue—Doxorubicin—breast cancer	1.78e-05	0.000322	CcSEcCtD
Gonadorelin—Pain—Doxorubicin—breast cancer	1.77e-05	0.000319	CcSEcCtD
Gonadorelin—Constipation—Doxorubicin—breast cancer	1.77e-05	0.000319	CcSEcCtD
Gonadorelin—Abdominal pain—Epirubicin—breast cancer	1.77e-05	0.000319	CcSEcCtD
Gonadorelin—Hypersensitivity—Methotrexate—breast cancer	1.76e-05	0.000317	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—NOTCH4—breast cancer	1.74e-05	0.0016	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—GZMB—breast cancer	1.73e-05	0.00159	CbGpPWpGaD
Gonadorelin—Asthenia—Methotrexate—breast cancer	1.71e-05	0.000309	CcSEcCtD
Gonadorelin—Gastrointestinal pain—Doxorubicin—breast cancer	1.69e-05	0.000305	CcSEcCtD
Gonadorelin—Pruritus—Methotrexate—breast cancer	1.69e-05	0.000305	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—AGTR2—breast cancer	1.67e-05	0.00155	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CXCL2—breast cancer	1.67e-05	0.00155	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PTHLH—breast cancer	1.66e-05	0.00153	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—BMP2—breast cancer	1.66e-05	0.00153	CbGpPWpGaD
Gonadorelin—Hypersensitivity—Epirubicin—breast cancer	1.65e-05	0.000297	CcSEcCtD
Gonadorelin—Abdominal pain—Doxorubicin—breast cancer	1.63e-05	0.000295	CcSEcCtD
Gonadorelin—Diarrhoea—Methotrexate—breast cancer	1.63e-05	0.000295	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—EDNRB—breast cancer	1.6e-05	0.00148	CbGpPWpGaD
Gonadorelin—Asthenia—Epirubicin—breast cancer	1.6e-05	0.000289	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PGR—breast cancer	1.59e-05	0.00147	CbGpPWpGaD
Gonadorelin—Pruritus—Epirubicin—breast cancer	1.58e-05	0.000285	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—THBS1—breast cancer	1.58e-05	0.00146	CbGpPWpGaD
Gonadorelin—Diarrhoea—Epirubicin—breast cancer	1.53e-05	0.000276	CcSEcCtD
Gonadorelin—Hypersensitivity—Doxorubicin—breast cancer	1.52e-05	0.000275	CcSEcCtD
Gonadorelin—Vomiting—Methotrexate—breast cancer	1.52e-05	0.000274	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—FLT1—breast cancer	1.51e-05	0.00139	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGF3—breast cancer	1.5e-05	0.00139	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SQSTM1—breast cancer	1.5e-05	0.00139	CbGpPWpGaD
Gonadorelin—Headache—Methotrexate—breast cancer	1.5e-05	0.00027	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CG—breast cancer	1.49e-05	0.00138	CbGpPWpGaD
Gonadorelin—Asthenia—Doxorubicin—breast cancer	1.48e-05	0.000268	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—JAG1—breast cancer	1.48e-05	0.00137	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NOTCH3—breast cancer	1.48e-05	0.00136	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PARP1—breast cancer	1.48e-05	0.00136	CbGpPWpGaD
Gonadorelin—Pruritus—Doxorubicin—breast cancer	1.46e-05	0.000264	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—CALCA—breast cancer	1.46e-05	0.00135	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RPS6—breast cancer	1.44e-05	0.00133	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGF4—breast cancer	1.43e-05	0.00132	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CXCL12—breast cancer	1.42e-05	0.00132	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CXCR4—breast cancer	1.42e-05	0.00132	CbGpPWpGaD
Gonadorelin—Vomiting—Epirubicin—breast cancer	1.42e-05	0.000256	CcSEcCtD
Gonadorelin—Nausea—Methotrexate—breast cancer	1.42e-05	0.000256	CcSEcCtD
Gonadorelin—Diarrhoea—Doxorubicin—breast cancer	1.41e-05	0.000255	CcSEcCtD
Gonadorelin—Headache—Epirubicin—breast cancer	1.4e-05	0.000253	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PAK1—breast cancer	1.4e-05	0.00129	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TCF7L2—breast cancer	1.37e-05	0.00127	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AKT2—breast cancer	1.37e-05	0.00126	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CG—breast cancer	1.36e-05	0.00125	CbGpPWpGaD
Gonadorelin—Nausea—Epirubicin—breast cancer	1.33e-05	0.000239	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—HSP90AA1—breast cancer	1.32e-05	0.00122	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NOTCH2—breast cancer	1.32e-05	0.00122	CbGpPWpGaD
Gonadorelin—Vomiting—Doxorubicin—breast cancer	1.31e-05	0.000237	CcSEcCtD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CD—breast cancer	1.31e-05	0.00121	CbGpPWpGaD
Gonadorelin—Headache—Doxorubicin—breast cancer	1.29e-05	0.000234	CcSEcCtD
Gonadorelin—GNRHR—Signaling Pathways—PRL—breast cancer	1.29e-05	0.00119	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AGTR1—breast cancer	1.29e-05	0.00119	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ADAM10—breast cancer	1.27e-05	0.00117	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—STK11—breast cancer	1.27e-05	0.00117	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PLG—breast cancer	1.25e-05	0.00116	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AKT2—breast cancer	1.24e-05	0.00115	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGF10—breast cancer	1.23e-05	0.00114	CbGpPWpGaD
Gonadorelin—Nausea—Doxorubicin—breast cancer	1.23e-05	0.000222	CcSEcCtD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CD—breast cancer	1.19e-05	0.0011	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PDGFA—breast cancer	1.19e-05	0.0011	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TGFBR2—breast cancer	1.17e-05	0.00108	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ITPR1—breast cancer	1.16e-05	0.00107	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ERBB4—breast cancer	1.15e-05	0.00106	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—STAT5A—breast cancer	1.15e-05	0.00106	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MMP3—breast cancer	1.15e-05	0.00106	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CB—breast cancer	1.14e-05	0.00106	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SMAD4—breast cancer	1.11e-05	0.00103	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IGF1R—breast cancer	1.1e-05	0.00102	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—CXCL8—breast cancer	1.1e-05	0.00102	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HES1—breast cancer	1.09e-05	0.001	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NCOR1—breast cancer	1.08e-05	0.000997	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PLA2G4A—breast cancer	1.08e-05	0.000997	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGF1—breast cancer	1.07e-05	0.000986	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CSF2—breast cancer	1.07e-05	0.000986	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—RAF1—breast cancer	1.06e-05	0.000983	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NRG1—breast cancer	1.06e-05	0.000978	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—H2AFX—breast cancer	1.05e-05	0.000971	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—IL2—breast cancer	1.05e-05	0.000971	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—E2F1—breast cancer	1.04e-05	0.000965	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CB—breast cancer	1.04e-05	0.00096	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SPP1—breast cancer	1e-05	0.000927	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—CXCL8—breast cancer	9.99e-06	0.000923	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ERBB3—breast cancer	9.92e-06	0.000917	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGFR2—breast cancer	9.91e-06	0.000915	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—IL2—breast cancer	9.55e-06	0.000882	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TERT—breast cancer	9.51e-06	0.000879	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FGFR1—breast cancer	9.23e-06	0.000853	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HIF1A—breast cancer	9.1e-06	0.00084	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—LEP—breast cancer	8.88e-06	0.00082	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CAV1—breast cancer	8.8e-06	0.000813	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—KDR—breast cancer	8.7e-06	0.000803	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ESR1—breast cancer	8.48e-06	0.000783	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—FN1—breast cancer	8.37e-06	0.000773	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NFKBIA—breast cancer	8.27e-06	0.000764	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NOTCH1—breast cancer	8.19e-06	0.000757	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—APC—breast cancer	8.01e-06	0.00074	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CG—breast cancer	8.01e-06	0.00074	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—KIT—breast cancer	8.01e-06	0.00074	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EGF—breast cancer	7.92e-06	0.000732	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—MAPK3—breast cancer	7.67e-06	0.000709	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—BRAF—breast cancer	7.53e-06	0.000696	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IGF1—breast cancer	7.34e-06	0.000678	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AKT2—breast cancer	7.33e-06	0.000677	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—EGFR—breast cancer	7.3e-06	0.000674	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CD—breast cancer	7.04e-06	0.000651	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—PIK3CA—breast cancer	6.98e-06	0.000645	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SERPINE1—breast cancer	6.97e-06	0.000644	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—KRAS—breast cancer	6.9e-06	0.000637	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—NOS3—breast cancer	6.65e-06	0.000614	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—PIK3CA—breast cancer	6.34e-06	0.000585	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MDM2—breast cancer	6.31e-06	0.000583	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RAF1—breast cancer	6.29e-06	0.000581	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—RELA—breast cancer	6.26e-06	0.000578	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—ERBB2—breast cancer	6.22e-06	0.000575	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MTOR—breast cancer	6.14e-06	0.000567	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CB—breast cancer	6.14e-06	0.000567	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CXCL8—breast cancer	5.9e-06	0.000545	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—HRAS—breast cancer	5.86e-06	0.000541	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CDKN1B—breast cancer	5.76e-06	0.000532	CbGpPWpGaD
Gonadorelin—GNRHR—GPCR downstream signaling—AKT1—breast cancer	5.7e-06	0.000527	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CASP3—breast cancer	5.65e-06	0.000522	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IL2—breast cancer	5.64e-06	0.000521	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—IL6—breast cancer	5.61e-06	0.000518	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CCND1—breast cancer	5.5e-06	0.000508	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—JUN—breast cancer	5.49e-06	0.000507	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CTNNB1—breast cancer	5.44e-06	0.000503	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MMP9—breast cancer	5.34e-06	0.000493	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—CDKN1A—breast cancer	5.32e-06	0.000491	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PTEN—breast cancer	5.31e-06	0.00049	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MAPK8—breast cancer	5.19e-06	0.000479	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling by GPCR—AKT1—breast cancer	5.18e-06	0.000478	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—SRC—breast cancer	4.92e-06	0.000454	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—VEGFA—breast cancer	4.79e-06	0.000443	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—STAT3—breast cancer	4.74e-06	0.000438	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MAPK3—breast cancer	4.53e-06	0.000419	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—MYC—breast cancer	4.41e-06	0.000407	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TGFB1—breast cancer	4.4e-06	0.000406	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—EGFR—breast cancer	4.31e-06	0.000398	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—KRAS—breast cancer	4.07e-06	0.000376	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—PIK3CA—breast cancer	3.74e-06	0.000346	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—TP53—breast cancer	3.62e-06	0.000334	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—HRAS—breast cancer	3.46e-06	0.00032	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—IL6—breast cancer	3.31e-06	0.000306	CbGpPWpGaD
Gonadorelin—GNRHR—Signaling Pathways—AKT1—breast cancer	3.06e-06	0.000282	CbGpPWpGaD
